Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Gilead Sciences Inc. (GILD) is moving its experimental drug combination against hepatitis C into a late- stage trial after it cured 95 percent of patients who used the medicine for eight weeks. The virus was undetectable in the blood of 19 of 20 patients who hadn’t received prior therapy eight weeks after finishing treatment with Gilead’s sofosbuvir and ledipasvir, the Foster City, California-based company said today in a statement. The length of the treatment is important because previously, the company had been focusing on 12-week course, said Mark Schoenebaum, a New York-based analyst at International Strategy & Investment Group LLC. Gilead is competing with drugmakers including AbbVie Inc. (ABBV) and Bristol-Myers Squibb Co. (BMY) in the quest for hepatitis C regimens that don’t involve injections of interferon, which can cause flu-like symptoms and depression.
Help employers find you! Check out all the jobs and post your resume.
